证券代码：837344 证券简称：三元基因 公告编号：2024-050 北京三元基因药业股份有限公司 2023 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 北京三元基因药业股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日在北京证券交易所官网（www.bse.cn）披露了《北京三元 基因药业股份有限公司 2023 年年度报告》（公告编号：2024-007）， 为方便广大投资者更深入了解公司 2023 年年度经营业绩的具体情 况，公司拟召开 2023 年年度报告业绩说明会。 申万宏源证券承销保荐有限责任公司保荐代表人： 徐鸿宇先生、潘志源先生 （二）会议召开地点 本次年度报告业绩说明会将采用网络远程的方式举行，投资者可 登陆中证路演中心（https://www.cs.com.cn/roadshow/）参与本次年 度业绩说明会。 三、 参加人员 公司董事长、总经理：程永庆先生 公司副总经理：刘金毅先生 公司财务负责人、副总经理：张凤琴女士 ...

Financial Performance - Operating revenue for Q1 2024 reached CNY 47,952,373.12, representing a 39.49% increase year-over-year [10]. - Net profit attributable to shareholders for Q1 2024 was CNY 1,928,398.18, up 9.87% from the same period last year [10]. - The company's gross profit margin increased, with operating costs rising by 41.20% to CNY 9,185,324.05 due to higher sales volume [12]. - The company’s basic earnings per share doubled to CNY 0.02 from CNY 0.01 in the previous year [10]. - Total revenue for Q1 2024 reached ¥47,952,373.12, a significant increase of 39.6% compared to ¥34,376,162.80 in Q1 2023 [43]. - Operating profit for Q1 2024 was ¥2,240,369.16, slightly up from ¥2,202,164.55 in Q1 2023, indicating a stable performance [44]. - Net profit for Q1 2024 was ¥1,928,398.18, representing a 9.8% increase from ¥1,755,211.84 in Q1 2023 [44]. - Earnings per share for Q1 2024 were ¥0.02, consistent with Q1 2023 [45]. Cash Flow and Assets - The net cash flow from operating activities was CNY 15,256,581.97, a significant increase of 233.62% compared to Q1 2023 [10]. - Operating cash inflow for Q1 2024 was CNY 66,423,147.36, a significant increase from CNY 36,843,520.22 in Q1 2023, representing an increase of 80.2% [48]. - Cash outflow for investment activities decreased to CNY 46,173,069.57 in Q1 2024 from CNY 108,461,515.10 in Q1 2023, indicating a reduction of 57.4% [49]. - Cash inflow from financing activities was CNY 32,523,874.00 in Q1 2024, down from CNY 77,700,006.08 in Q1 2023, a decrease of 58.2% [49]. - The ending cash and cash equivalents balance for Q1 2024 was CNY 157,128,684.11, down from CNY 180,526,369.49 in Q1 2023 [49]. - Total current assets decreased to CNY 276,537,250.04 from CNY 306,918,274.64, a decline of approximately 9.9% [37]. - Cash and cash equivalents decreased to CNY 157,128,684.11 from CNY 177,507,670.01, a decrease of about 11.5% [37]. - Accounts receivable decreased to CNY 70,872,074.34 from CNY 83,602,734.13, representing a decline of approximately 15.3% [37]. - Total non-current assets increased to CNY 944,751,490.26 from CNY 928,255,592.19, an increase of about 1.5% [38]. - Total assets as of March 31, 2024, were CNY 1,221,288,740.30, a decrease of 1.12% compared to the end of 2023 [10]. Liabilities and Equity - The asset-liability ratio for the consolidated entity decreased to 49.75% from 50.54% year-over-year [10]. - Total liabilities decreased to CNY 607,605,085.13 from CNY 624,235,299.84, a reduction of approximately 2.6% [39]. - Total equity increased to CNY 613,683,655.17 from CNY 610,938,566.99, an increase of about 0.4% [39]. - Long-term borrowings increased to CNY 438,250,530.75 from CNY 414,229,240.81, an increase of approximately 5.8% [39]. - The largest shareholder, Beijing Southeast Pharmaceutical Investment Holding Co., Ltd., holds 46,907,925 shares, accounting for 38.51% of the total shares [19]. Research and Development - The company has completed the Phase III clinical trial for interferon α1b nebulization treatment for RSV pneumonia in children, showing significant efficacy and safety, with a reduction in clinical symptom duration by nearly one day within 72 hours of treatment [28]. - The company has initiated a Phase III clinical trial for interferon α1b in the prevention and treatment of COVID-19, with 400 patients enrolled across three newly approved clinical centers [29]. - The predictive accuracy for E antigen seroconversion and S antigen negativity in the new PEG-integrated interferon clinical trial has reached 84% and 75%, respectively [30]. - The company has improved the expansion process of γδT cells from 450 times to 16,000 times, significantly increasing the yield of cell preparations for tumor immunotherapy [31]. - Research and development expenses for Q1 2024 were ¥2,924,856.44, up from ¥2,518,540.70 in Q1 2023, highlighting a focus on innovation [43]. Operational Developments - The new intelligent production and R&D base has been recognized as a key project by the Beijing government, with an annual production capacity exceeding 100 million units across various dosage forms [32]. - The new facility incorporates advanced technologies such as industrial internet and big data analysis, aiming to enhance operational efficiency and reduce costs [33]. - The construction of the new facility has entered the completion and acceptance phase, with various approvals obtained from local authorities [34]. Commitments and Legal Matters - There are no significant changes in the disclosed commitments, and all commitments have been strictly adhered to [24]. - There are no litigation or arbitration matters reported during the reporting period [22]. - The company has not experienced any significant changes in shareholder equity or major transactions during the reporting period [22].

证券代码：837344 证券简称：三元基因 公告编号：2024-048 北京三元基因药业股份有限公司 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 24 日 4.发出董事会会议通知的时间和方式：2024 年 4 月 13 日以通讯 方式发出。 5.会议主持人：会议由程永庆董事长主持。 6.会议列席人员：监事会成员、董事会秘书以及公司其他高级管 理人员列席了会议。 7.召开情况合法、合规、合章程性说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事程十庆因公务出差以通讯方式参与表决。 董事杨大军因公务出差以通讯方式参与表决。 2.议案表决结果：同意 7 票；反对 0 票；弃权 0 票。 上述议案已经董事会审计委员会会议审议通过。 3.回避表 ...

| 1-5 | | --- | | 6-7 | | 8 | | 9 | | 10-11 | | 12-13 | | 14 | | 15 | | 16-17 | | 18-91 | CAC [2024]0033 CAC [2024]0033 2023 12 31 2023 2023 12 31 2023 1 2023 1 1 24,473.30 2 1 5 6 7 1. 2023 11,316.96 2023 8,443.54 2. 2 3 4 1 2 2 3 4 5 6 7 2023 3 治理层负责监督北京三元基因公司的财务报告过程。 六、注册会计师对财务报表审计的责任 我们的目标是对财务报表整体是否不存在由于舞弊或错误导致的重大错报获取 合理保证,并出具包含审计意见的审计报告。合理保证是高水平的保证,但并不能 保证按照审计准则执行的审计在某一重大错报存在时总能发现。错报可能由于舞弊 或错误导致,如果合理预期错报单独或汇总起来可能影响财务报表使用者依据财务 报表作出的经济决策,则通常认为错报是重大的。 在按照审计准则执行审计工作的过程中,我们运用职业判断,并保持职业怀疑。 同时,我们也执行以下工作: (1) ...

Financial Performance - The company achieved operating revenue of CNY 245 million, a year-on-year increase of 43.12%, and a net profit of CNY 29.09 million, up 40.41% year-on-year[5]. - The company’s net profit attributable to shareholders for 2023 was ¥31,681,717.59, a 2.00% increase from ¥31,059,442.05 in 2022[52]. - The company reported a revenue growth of 43.12% during the reporting period, with a net profit growth of 40.41% after deducting non-recurring items[175]. - The company’s operating cash flow net amount was 42.76 million RMB, with a product gross margin of 79.69%[29]. - The company’s gross profit margin for 2023 was 79.69%, slightly down from 80.03% in 2022[52]. - The company experienced a significant increase in other business income, which surged by 8428.29% to ¥48,302.55[91]. - The company’s human interferon α1b injection experienced an average price reduction of 19.38% following the procurement results from the interferon industry[154]. Research and Development - The company has developed a new drug, recombinant human interferon α1b, which is the first genetically engineered drug with independent intellectual property rights in China[6]. - The company is actively advancing four major new drug research projects and has a complete R&D team that has achieved significant results[6]. - The company’s R&D expenditures increased by 44.72% to 121.21 million, driven by clinical trials for new treatments[19]. - The company is conducting a Phase III clinical trial for nebulized human interferon α1b treatment for pediatric RSV pneumonia, which addresses a significant clinical need in treating respiratory infections in children[70]. - The company is conducting a Phase III clinical trial for interferon α1b to treat COVID-19, which is expected to enhance its market share and brand influence significantly[114]. - The company is developing new clinical value products, such as γδT cell therapy, which aligns with its existing product lines and reduces innovation risks[179]. Market Expansion and Sales Strategy - The company added 460 new medical terminals in regions benefiting from exclusive procurement, with sales in Henan and Guangdong increasing by 308.96% and 345.30% year-on-year, respectively[13]. - The company has established a robust sales network that ensures its products reach various healthcare service endpoints nationwide[66]. - The company is actively expanding its marketing network, focusing on city-level hospitals and grassroots medical markets, to enhance its sales strategy and achieve annual sales targets[82]. - The company is focusing on the growing demand for pediatric medications, with policies expected to stimulate the development of this market segment[74]. - The company has successfully expanded its market presence, with sales volume in certain regions increasing by over 300% despite a decrease in profit margins due to competitive pricing[94]. Technological Advancements - The company is implementing an "Industry 4.0" strategy in its new intelligent production and R&D base, utilizing advanced technologies such as big data and artificial intelligence[9]. - The company has established five technology platforms to support the development of various drug formulations, including injection solutions and inhalation agents[6]. - The new intelligent production and R&D base project is designed to achieve an annual production capacity of over 100 million units, including various dosage forms such as powder injections and nebulized inhalation agents[74]. - The company has introduced advanced information systems such as SCADA, DCS, and MES in its new plant to enhance production efficiency and quality, aiming for cost reduction and efficiency improvement[142]. Financial Position and Assets - Cash and cash equivalents decreased by 21.26% to 177.51 million, accounting for 14.37% of total assets[17]. - Accounts receivable increased by 17.09% to 83.60 million, representing 6.77% of total assets[17]. - Construction in progress surged by 138.83% to 639.37 million, now comprising 51.76% of total assets[17]. - Total assets at the end of 2023 reached ¥1,235,173,866.83, a 32.30% increase from ¥933,631,678.93 at the end of 2022[57]. - The company's total equity attributable to shareholders was ¥610,938,566.99, a 6.28% increase from ¥574,814,325.65 in 2022[57]. Government Support and Industry Trends - The biopharmaceutical industry is receiving increased policy support from the government, which is expected to drive high-quality development in the sector[14]. - The government has introduced favorable policies for the pharmaceutical industry, aiming to enhance innovation and competitiveness, which is expected to drive demand for medical products[88]. - The government has increased support for the biopharmaceutical industry, encouraging drug innovation and prioritizing the review and approval of innovative drugs[71]. Corporate Social Responsibility and Recognition - The company was recognized as a 2023 Forbes China ESG Innovative Enterprise at the Forbes China ESG Innovation Enterprise Selection Summit[29]. - The company actively participated in social responsibility initiatives, including rural poverty alleviation and community support activities during the reporting period[132]. - The company has been recognized as "2022 China's Annual Preferred Employer" and "2023 China's Annual Preferred Employer" by Peking University and Zhaopin[140]. - The company has received numerous certifications and awards, including being recognized as a National High-tech Enterprise and a National Intellectual Property Demonstration Enterprise[69]. Risk Management - The company has faced risks related to increased competition in the biopharmaceutical sector, necessitating a focus on differentiation and clinical evidence to support new indications for its products[178]. - The company has not reported any significant changes in major risks during the reporting period[181]. - There are no new risk factors identified during the reporting period[182].

北京三元基因药业股份有限公司 2023 年度募集资金存放与实际使用情况 鉴证报告 CAC 证专字[2024]0048 号 中审华会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn） "进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn） "进行查... " | 달 录 | | | --- | --- | | 目录 | 页次 | | 一、募集资金年度存放与实际使用情况鉴证报告 | 1-2 | | 二、北京三元基因药业股份有限公司 2022年度募集资金存放与 | 3-7 | 实际使用情况的专项报告 募集资金年度存放与实际使用情况鉴证报告 CAC 证专字[2024]0048 号 北京三元基因药业股份有限公司全体股东: 我们接受委托,对后附的北京三元基因药业股份有限公司(以下简称贵公司) 《2023 年度募集资金存放与实际使用情况的专项报告》进行了鉴证。 一、对报告使用者和使用目的的限定 本鉴证报告仅供贵公司年度报告披露时使用,不得用作任何其他目的。我们 同意将本鉴证报告作为贵公司年度 ...

证券代码：837344 证券简称：三元基因 公告编号：2024-038 北京三元基因药业股份有限公司 独立董事工作制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 本制度经公司 2024 年 4 月 11 日召开第三届董事会第十六次会议 审议通过，议案表决结果：同意 7 票，反对 0 票，弃权 0 票。该议案 仍需提交股东大会审议。 二、 制度的主要内容，分章节列示： 北京三元基因药业股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善北京三元基因药业股份有限公司（以下简 称"公司"）法人治理结构建设，为独立董事创造良好的工作环境， 促进公司规范运行，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》《上市公司独立董事管理办法》《北 京证券交易所股票上市规则（试行）》（以下简称"《上市规则》"）《北 京证券交易所上市公司持续监管办法（试行）》《北京证券交易所上市 公司持续监管指引第 1 号——独立董事》（以下简称"《指引第 1 号》" ...

证券代码：837344 证券简称：三元基因 公告编号：2024-019 北京三元基因药业股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、募集资金基本情况 公司 2020 年 12 月向不特定合格投资者公开发行股票并在精选 层挂牌募集资金的基本情况： 根据中国证券监督管理委员会《关于核准北京三元基因药业股 份有限公司向不特定合格投资者公开发行股票的批复》（证监许可 [2020]3321 号），公司向不特定合格投资者公开发行了人民币普通 股 1,131 万股，发行价格为 25.00 元/股，募集资金总额为人民币 282,750,000.00 元，扣除各项发行费用人民币 22,717,500.00 元，募 集资金净额为人民币 260,032,500.00 元。 本次募集资金到账时间为 2020 年 12 月 30 日，本次募集资金 到位情况已经中审华会计师事务所（特殊普通合伙）审验，并出具 CAC 证验字[2020]0250 号《验资报告》。 司章程，结 ...

证券代码：837344 证券简称：三元基因 公告编号：2024-027 北京三元基因药业股份有限公司 董事任命公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、任免基本情况 （一）任免的基本情况 根据《公司法》、《北京证券交易所股票上市规则（试行）》、《上市公司 独立董事管理办法》、《北京证券交易所上市公司持续监管指引第 1 号—— 独立董事》及《公司章程》等相关规定，北京三元基因药业股份有限公司 董事会提名胡左浩为公司第三届董事会独立董事候选人，提名张凤琴为公 司第三届董事会董事候选人。 2024 年 4 月 11 日，公司召开了第三届董事会第十六次会议，审议通 过《关于提名胡左浩先生为公司第三届董事会独立董事的议案》，同意提名 胡左浩先生为公司第三届董事会独立董事候选人，任期自公司 2023 年年度 股东大会审议通过之日起至第三届董事会届满之日止；审议通过《关于提 名张凤琴女士为公司第三届董事会董事的议案》，同意提名张凤琴女士为公 司第三届董事会董事候选人，任期自公司 2023 年年度股东大会 ...

证券代码：837344 证券简称：三元基因 公告编号：2024-012 北京三元基因药业股份有限公司 （一）独立董事及其配偶、父母、子女、具有主要社会关系的人 员未在公司或公司附属企业任职； （二）独立董事及其配偶、父母、子女未直接或间接持有公司已 发行股份百分之一以上，不是公司前十名股东中的自然人股东； （三）独立董事及其配偶、父母、子女不是直接或间接持有公司 已发行股份百分之五以上的股东，未在公司前五名股东任职； （四）独立董事及其配偶、父母、子女未在公司控股股东、实际 控制人的附属企业任职； （五）独立董事不是公司及公司控股股东、实际控制人或者其各 自的附属企业有重大业务往来的人员，未在有重大业务往来的单位及 其控股股东、实际控制人任职； （六）独立董事不是为公司及公司控股股东、实际控制人或者其 各自附属企业提供财务、法律、咨询、保荐等服务的人员，包括但不 限于提供服务的中介机构的项目组全体人员、各级复核人员、在报告 上签字的人员、合伙人、董事、高级管理人员及主要负责人； （七）独立董事最近十二个月内未曾经具有第一项至第六项所列 举情形； （八）独立董事不是法律、行政法规、中国证监会规定、证券交 易所业 ...